Oncolytics Biotech Inc. announced that the Company received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC). The FDA supports progression-free survival as the primary endpoint of the study, with overall survival as a key secondary endpoint. The Company's proposed study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 CAD | +0.71% |
|
+2.92% | -21.23% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.23% | 78.38M | |
+18.36% | 45.34B | |
+42.49% | 40.42B | |
-9.47% | 37.92B | |
+31.17% | 31.75B | |
-7.79% | 27.71B | |
+13.27% | 26.52B | |
+42.64% | 13.96B | |
+32.04% | 12.44B | |
-6.09% | 11.26B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Announces Productive FDA Type C Meeting on Its Metastatic Breast Cancer Program